Lung Cancer
News from the FDA/CDC
E-cigarettes most popular among youngest adults
CDC estimates that over 15% of U.S. adults have at least tried vaping.
News
FDA approves biosimilar to bevacizumab
Bevacizumab-awwb is approved for the treatment of adults with certain colorectal, lung, brain, kidney, and cervical cancers.
Latest News
Analysis: Actual cancer drug R&D costs are far less than widely publicized sum
Research and development costs for cancer drugs may be far lower than previous estimates, casting doubt on common justifications by drug companies...
Conference Coverage
Osimertinib bests PFS achieved with standard care for EGFR-mutated NSCLC
More answers are needed about the final number of patients who are able to crossover to osimertinib, and about the mechanism and management of...
Conference Coverage
PACIFIC: Durvalumab extends PFS in stage 3 NSCLC
From the Journals
Pembrolizumab showed ‘promising’ antitumor activity in small-cell lung cancer
The objective response rate was 33% in the phase 1b KEYNOTE-028 study of 24 patients with extensive-stage small cell lung cancer.
Conference Coverage
CANTOS sings of novel strategy for cardiovascular, cancer prevention
BARCELONA – Targeted anti-inflammatory therapy with canakinumab showed diverse clinical benefits.
Conference Coverage
VIDEO: Inflammation’s role in atherosclerosis confirmed in CANTOS
BARCELONA – Inflammation as a treatment target is definitively shown in the CANTOS trial.
Conference Coverage
Cancer screening in elderly: When to just say no
ESTES PARK, COLO. – Move beyond chronologic age to individualize cancer screening in the elderly based on physiologic age and benefits vs. harms...
Conference Coverage
Wide variability found in invasive mediastinal staging rates for lung cancer
COLORADO SPRINGS – There was a fivefold difference between hospitals in Washington state.